{"Symbol": "ATHE", "AssetType": "Common Stock", "Name": "Alterity Therapeutics Ltd", "Description": "Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinson's disease and other neurodegenerative diseases in Australia. The company is headquartered in Melbourne, Australia.", "CIK": "1131343", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "350 COLLINS STREET, MELBOURNE, VIC, AUSTRALIA, 3000", "OfficialSite": "https://alteritytherapeutics.com", "FiscalYearEnd": "June", "LatestQuarter": "2025-06-30", "MarketCapitalization": "63177000", "EBITDA": "-14633244", "PERatio": "None", "PEGRatio": "None", "BookValue": "0.0035", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-0.62", "RevenuePerShareTTM": "0.6", "ProfitMargin": "-2.233", "OperatingMarginTTM": "-1.857", "ReturnOnAssetsTTM": "-0.281", "ReturnOnEquityTTM": "-0.432", "RevenueTTM": "5438900", "GrossProfitTTM": "5311400", "DilutedEPSTTM": "-0.62", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0.809", "AnalystTargetPrice": "11", "AnalystRatingStrongBuy": "-", "AnalystRatingBuy": "-", "AnalystRatingHold": "-", "AnalystRatingSell": "-", "AnalystRatingStrongSell": "-", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "11.62", "PriceToBookRatio": "2.091", "EVToRevenue": "113.99", "EVToEBITDA": "0.755", "Beta": "-0.016", "52WeekHigh": "7", "52WeekLow": "2.521", "50DayMovingAverage": "3.287", "200DayMovingAverage": "4.168", "SharesOutstanding": "18125700", "SharesFloat": "7037971000", "PercentInsiders": "0.000", "PercentInstitutions": "1.830", "DividendDate": "None", "ExDividendDate": "None"}